TY - JOUR
T1 - Locally advanced non-metastatic breast cancer
T2 - Analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach
AU - Gardin, G.
AU - Rosso, R.
AU - Campora, E.
AU - Repetto, L.
AU - Naso, C.
AU - Canavese, G.
AU - Catturich, A.
AU - Corvò, R.
AU - Guenzi, M.
AU - Pronzato, P.
AU - Baldini, E.
AU - Conte, P. F.
PY - 1995
Y1 - 1995
N2 - 125 stage III breast cancer patients, including 51 cases of inflammatory carcinoma, were treated with the following combined modality approach: three courses of primary 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) chemotherapy followed by locoregional treatment and subsequent adjuvant chemotherapy consisting of three courses of FAC alternating with three courses of cyclophosphamide, methotrexate, 5-fluorouracil (CMF). Clinical response to primary FAC was 65% (complete 10%). Residual tumour mass in the mastectomy specimen was > 1 and ≤ 1 cm in 82 and 18% of cases, respectively. Complete pathological response following primary chemotherapy was achieved in only 3.5% of cases. After primary FAC and local treatment, 97% of patients were disease-free. Overall survival (S) and progression-free survival (PFS) at 5 years were 56 and 34%, respectively. Univariate analysis showed that age, receptor status and clinical and pathological response to primary chemotherapy did not appear to influence treatment outcome significantly, whereas stage, presence of inflammatory disease and number of involved nodes had a significant impact on both S and PFS.
AB - 125 stage III breast cancer patients, including 51 cases of inflammatory carcinoma, were treated with the following combined modality approach: three courses of primary 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) chemotherapy followed by locoregional treatment and subsequent adjuvant chemotherapy consisting of three courses of FAC alternating with three courses of cyclophosphamide, methotrexate, 5-fluorouracil (CMF). Clinical response to primary FAC was 65% (complete 10%). Residual tumour mass in the mastectomy specimen was > 1 and ≤ 1 cm in 82 and 18% of cases, respectively. Complete pathological response following primary chemotherapy was achieved in only 3.5% of cases. After primary FAC and local treatment, 97% of patients were disease-free. Overall survival (S) and progression-free survival (PFS) at 5 years were 56 and 34%, respectively. Univariate analysis showed that age, receptor status and clinical and pathological response to primary chemotherapy did not appear to influence treatment outcome significantly, whereas stage, presence of inflammatory disease and number of involved nodes had a significant impact on both S and PFS.
KW - breast cancer
KW - locally advanced
KW - multimodality treatment
KW - prognostic factors
KW - univariate analysis
UR - http://www.scopus.com/inward/record.url?scp=0029156990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029156990&partnerID=8YFLogxK
U2 - 10.1016/0959-8049(95)00199-S
DO - 10.1016/0959-8049(95)00199-S
M3 - Article
C2 - 7577066
AN - SCOPUS:0029156990
VL - 31
SP - 1428
EP - 1433
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 9
ER -